Skip to content

Study · In vitro (cells) · staphylococcus aureus · 2017

1 result

Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis.

Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, Shafiq F, Kotol PF, Bouslimani A, Melnik AV, Latif H, Kim JN and 12 more

Show all authors

Lockhart A, Artis K, David G, Taylor P, Streib J, Dorrestein PC, Grier A, Gill SR, Zengler K, Hata TR, Leung DY, Gallo RL

Science translational medicine1 Feb 2017Cited by 856 (Europe PMC)

PMID28228596 (opens in a new tab)PMCIDPMC5600545 (opens in a new tab)DOI10.1126/scitranslmed.aah4680 (opens in a new tab)PepBankPUB-28228596
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In lab tests, antimicrobial peptides from coagulase-negative staphylococci that kill S. aureus acted together (synergized) with the human peptide LL‑37.

    In plain wordsIn lab tests, LL‑37 worked together with peptides made by skin bacteria to kill Staphylococcus aureus.

    Peptide
    LL-37
    Outcome
    IncreaseSynergy with CoNS antimicrobial peptides against S. aureus
    Study

    Staphylococcus aureusn: not reported in source

    In vitro bacterial killing assay
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These AMPs were strain-specific, highly potent, selectively killed S. aureus, and synergized with the human AMP LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.